Presented late last monthIn 16º Annual Workshop on Clinical Pharmacology of HIV and Hepatitis C Treatment in Washington, DC, shows a promise for a monthly PrEP, or even injectable and quarterly, Cabotegravir dose. "By the time I saw the first poster on A GSK744 from IAS in Washington, DC, at 2012's July conference, I immediately recognized that this was the presentation, this was the presentation sofa at the conference," said Jules Levin, Executive Director of NATAP, who presented the update. "This would be a major evolution in the treatment of HIV and Prep. Imagine - treatment of HIV delivered once every three months, for injectable use, and prepare, each to face three months, for injectable use. What is a great development, a breakthrough in science. "Cabotegravir, is a long-acting integrase inhibitor. It is a new generation of medications, unlike the currently used Truvada of Gilead, in use as Prep these days, which has been a "star over many years. Cabotegravir, also known as A GSK 444, has not yet been approved by the US Food and Drug Administration. It is being developed jointly by Glaxo Smith Kline and ViiV Healthcare. Used as Prep, the drug is in phase II and III clinical trials among men who have sex with men and transgender as well as women in the Americas and Thailand. It has already been proven to be safe and effective in preventing vaginal transmission of HIV in monkeys. The results of the PrEP tests on men are expected by the end of this year and early next year. Used as an usolonggo and long-term injectable treatment in the treatment of HIV-infected persons. It is expected to introduce the Cabotegravir phase III trials, along with another drug, Rilpivarine, early next year. The news is important because PrE detractors, largely Michael Weinstein of the AIDS Healthcare Foundation, say those who have HIV are likely to be non-adherent. An injectable version, which guarantees long lasting delivery, health in a clear definition. Preliminary trials have already demonstrated efficacy and safety. The drug would be injected into the buttocks. Used as Prep, Cabotegravir can initially be implanted orally to accelerate approval. Levin concluded his presentation last month stating "substantial progress" in the development and proven effectiveness ofCabotegraviras PrEP By: David Heitz June 14th, 2015 TAGS: Translated from originalInjectable PREP? IT MAY BE AVAILABLE SOONER THAN YOU THINK by Claudio de Souza Santoson 14 June 2015.